PL1749090T3 - Sposób formułowania i kompozycja do terapii komórkowej - Google Patents

Sposób formułowania i kompozycja do terapii komórkowej

Info

Publication number
PL1749090T3
PL1749090T3 PL05724065T PL05724065T PL1749090T3 PL 1749090 T3 PL1749090 T3 PL 1749090T3 PL 05724065 T PL05724065 T PL 05724065T PL 05724065 T PL05724065 T PL 05724065T PL 1749090 T3 PL1749090 T3 PL 1749090T3
Authority
PL
Poland
Prior art keywords
composition
cell therapy
formulation method
therapy formulation
cell
Prior art date
Application number
PL05724065T
Other languages
English (en)
Inventor
Michael Har-Noy
Original Assignee
Immunovative Therapies, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies, Ltd. filed Critical Immunovative Therapies, Ltd.
Publication of PL1749090T3 publication Critical patent/PL1749090T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
PL05724065T 2004-03-01 2005-03-01 Sposób formułowania i kompozycja do terapii komórkowej PL1749090T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54903204P 2004-03-01 2004-03-01
EP05724065.7A EP1749090B1 (en) 2004-03-01 2005-03-01 Cell therapy formulation method and composition
PCT/US2005/006446 WO2005084276A2 (en) 2004-03-01 2005-03-01 Cell therapy formulation method and composition

Publications (1)

Publication Number Publication Date
PL1749090T3 true PL1749090T3 (pl) 2017-12-29

Family

ID=34919427

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05724065T PL1749090T3 (pl) 2004-03-01 2005-03-01 Sposób formułowania i kompozycja do terapii komórkowej

Country Status (10)

Country Link
EP (2) EP1749090B1 (pl)
JP (3) JP5144250B2 (pl)
CA (1) CA2530514C (pl)
DK (1) DK1749090T3 (pl)
ES (1) ES2635868T3 (pl)
HU (1) HUE035726T2 (pl)
IL (3) IL173405A (pl)
PL (1) PL1749090T3 (pl)
PT (1) PT1749090T (pl)
WO (1) WO2005084276A2 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
PL2573166T3 (pl) 2004-02-26 2016-11-30 Sposoby otrzymywania komórek T do terapii komórkowej
CA2838041C (en) 2011-05-03 2018-09-25 Immunovative Therapies, Ltd. Methods for handling biological drugs containing living cells
US9233156B2 (en) 2011-05-03 2016-01-12 Immunovative Therapies Ltd. Induction of IL-12 using immunotherapy
CN105899219B (zh) * 2014-01-08 2021-08-13 免疫创新治疗有限公司 人类免疫缺陷病毒/获得性免疫缺陷综合症的治疗

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
AU5729294A (en) * 1992-11-25 1994-06-22 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
ES2240962T3 (es) * 1993-06-04 2005-10-16 The United States Of America As Represented By The Secretary Of The Navy Metodo para estimular selectivamente la proliferacion de celulas t.
CA2168950A1 (en) 1993-08-06 1995-02-16 Esteban Celis Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
CA2191586A1 (en) * 1994-06-03 1995-12-14 Carl H. June Methods for selectively stimulating proliferation of t cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
ES2201177T3 (es) 1995-03-08 2004-03-16 The Scripps Research Institute Sistema de presentacion de antigenos y activacion de celulas-t.
WO1998033891A1 (en) 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
WO2003038062A2 (en) * 2001-10-31 2003-05-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Generation of use of tc1 and tc2 cells
WO2003057171A2 (en) * 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
PL2573166T3 (pl) * 2004-02-26 2016-11-30 Sposoby otrzymywania komórek T do terapii komórkowej

Also Published As

Publication number Publication date
WO2005084276A2 (en) 2005-09-15
EP3202895A1 (en) 2017-08-09
JP2012021033A (ja) 2012-02-02
HUE035726T2 (en) 2018-05-28
JP2007526314A (ja) 2007-09-13
DK1749090T3 (en) 2017-09-04
IL223938B (en) 2020-01-30
EP1749090A4 (en) 2009-04-29
PT1749090T (pt) 2017-08-28
JP5649551B2 (ja) 2015-01-07
EP1749090A2 (en) 2007-02-07
JP2014077018A (ja) 2014-05-01
ES2635868T3 (es) 2017-10-05
JP5144250B2 (ja) 2013-02-13
WO2005084276A3 (en) 2007-05-10
IL173405A0 (en) 2006-06-11
IL210244A0 (en) 2011-03-31
IL173405A (en) 2011-02-28
CA2530514A1 (en) 2005-09-15
EP1749090B1 (en) 2017-05-17
CA2530514C (en) 2017-01-31

Similar Documents

Publication Publication Date Title
HRP20181270T1 (hr) Direktno komprimirana formulacija i postupak
GB0422525D0 (en) Dermatological compositions and methods
IL189079A0 (en) Method of encapsulating therapeutic substances in cells
SI1753406T1 (sl) Formulacija in postopek za oplaščenje tablet
GB0505446D0 (en) Polishing composition and polishing method
GB2412919B (en) Polishing composition and polishing method
IL177793A0 (en) Method and composition for burned skin
EP1841397A4 (en) TRICHOLOGY FORMULATIONS AND TREATMENTS
GB0416252D0 (en) Cosmetic method and composition
GB0404327D0 (en) Pharmaceutical composition and method of using same
IL184062A0 (en) Visco-supplement composition and methods
SG115786A1 (en) Polishing composition and polishing method
EP1765373A4 (en) OZONIZED PHARMACEUTICAL COMPOSITION AND METHOD THEREOF
PL1749090T3 (pl) Sposób formułowania i kompozycja do terapii komórkowej
ZA200605722B (en) Composition and method
ZA200706038B (en) Visco-supplement composition and methods
EP1812032A4 (en) TISSUE FACTOR COMPOSITION AND RELATED METHODS
GB0608399D0 (en) Pharmaceutical composition and method of using same
GB0407993D0 (en) Therapeutic methods and compositions for use therein
GB0418363D0 (en) Therapeutic methods and compositions for use therein
GB0411093D0 (en) Method and composition
GB0406949D0 (en) Composition and method
GB0417415D0 (en) Composition and method
GB0425737D0 (en) Composition and method
GB0426756D0 (en) Composition and method